Details of the Drug

General Information of Drug (ID: DM9Y6X7)

Drug Name

Clodronate

Synonyms

Bonefos; Clodronsaeure; Dichloromethanediphosphonate; Dichloromethylenebisphosphonate; Methanedichlorodiphosphonate; Acide clodronique; Acido clodronico; Acidum clodronicum; Clodronic Acid; Dichloromethanediphosphonic acid; Dichloromethylene Biphosphonate; Dichloromethylene Diphosphonate; Dichloromethylidene diphosphonate; Liposomes containing clodronic acid; Methanedichlorodiphosphonic acid; Acid, Clodronic; Acid, Dichloromethanediphosphonic; Acide clodronique [INN-French]; Acido clodronico [INN-Spanish]; Acidum clodronicum [INN-Latin]; Biphosphonate, Dichloromethylene; Bonefos (TN); Clodron (TN); Diphosphonate, Dichloromethane; Diphosphonate, Dichloromethylene; Disodium, Clodronate; Loron (TN); Sodium, Clodronate; [dichloro(phosphono)methyl]phosphonic acid; Clodronic acid (USAN/INN); Clodronic acid [USAN:BAN:INN]; Dichlormethylen-bis(phosphonsaeure); Dichloromethylene-1,1-bisphosphonic acid; Dichloromethylene-1,1-diphosphonic acid; Phosphonic acid, (dichloromethylene)di-(8CI); (Dichloro-phosphono-methyl)-phosphonic acid; (Dichloromethylene)bisphosphonic acid; (Dichloromethylene)diphosphonic acid; (Lip-C); (dichloromethanediyl)bis(phosphonic acid)

Indication

Disease Entry	ICD 11	Status	REF
Hypercalcaemia	5B91.0	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypocalcemic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

244.89

Logarithm of the Partition Coefficient (xlogp)

-2.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 44.2 mgh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 16.1 mg/L [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
Bioavailability: The bioavailability of drug is 1-2% [2]
Clearance: The renal clearance of drug is 90 mL/min [4]
Elimination: 80% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 5.6 hours [4]
Metabolism: The drug is not metabolised [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.64% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.88 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.395 mg/mL [3]

Chemical Identifiers

Formula: CH4Cl2O6P2
IUPAC Name: [dichloro(phosphono)methyl]phosphonic acid
Canonical SMILES: C(P(=O)(O)O)(P(=O)(O)O)(Cl)Cl
InChI: InChI=1S/CH4Cl2O6P2/c2-1(3,10(4,5)6)11(7,8)9/h(H2,4,5,6)(H2,7,8,9)
InChIKey: ACSIXWWBWUQEHA-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 25419
ChEBI ID: CHEBI:110423
CAS Number: 10596-23-3
DrugBank ID: DB00720
TTD ID: D00HNB
VARIDT ID: DR00994

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenine nucleotide translocator 1 (SLC25A4)	TTU5A6Q	ADT1_HUMAN	Inhibitor	[6]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
(E3-independent) E2 ubiquitin-conjugating enzyme	OTHGS2VA	UBE2O_HUMAN	Gene/Protein Processing	[7]
(Lyso)-N-acylphosphatidylethanolamine lipase (ABHD4)	OTQK3M9X	ABHD4_HUMAN	Gene/Protein Processing	[7]
14-3-3 protein sigma (SFN)	OTLJCZ1U	1433S_HUMAN	Gene/Protein Processing	[7]
3'-5' RNA helicase YTHDC2	OTYDYKDY	YTDC2_HUMAN	Gene/Protein Processing	[7]
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Gene/Protein Processing	[7]
5'-AMP-activated protein kinase subunit beta-2 (PRKAB2)	OTLVN68B	AAKB2_HUMAN	Gene/Protein Processing	[7]
6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4)	OTQYEXL2	F264_HUMAN	Gene/Protein Processing	[7]
ABC-type oligopeptide transporter ABCB9 (ABCB9)	OTSOBOL5	ABCB9_HUMAN	Gene/Protein Processing	[7]
ADP-ribosylation factor-like protein 1 (ARL1)	OTB6N6BR	ARL1_HUMAN	Gene/Protein Processing	[7]
Agrin (AGRN)	OTWJENAZ	AGRIN_HUMAN	Gene/Protein Processing	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Current and future treatments of bone metastases. Expert Opin Emerg Drugs. 2008 Dec;13(4):609-27.
2	Frediani B, Cavalieri L, Cremonesi G: Clodronic acid formulations available in Europe and their use in osteoporosis: a review. Clin Drug Investig. 2009;29(6):359-79. doi: 10.2165/00044011-200929060-00001.
3	BDDCS applied to over 900 drugs
4	Health Canada Approved Drug Products: Clodronate Oral Capsules
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol. 2002 May;61(5):1255-62.
7	Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.